Final analysis of our experience with Lu-177-PSMA radioligand treatment at Emory University

被引：0
|
作者：
Chopra, Jigyasa [1 ]
Muzahir, Saima [1 ]
Galt, James [1 ]
Abiodun-Ojo, Olayinka [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242357
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pre- or Post-Chemotherapy: Effect of 177Lu-PSMA Radioligand Therapy on PSMA Expression
    Yadav, Surekha
    Heath, Courtney Lawhn
    Juarez, Roxanna
    De Kouchkovsky, Ivan
    Aggarwal, Rahul
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [42] PSMA Radioligand Therapy of Metastasized Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: First comparative Dosimetric Results
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S36 - S37
  • [43] Self-radiolysis rate of small-molecule Lu-177-PSMA verified with external irradiation
    Reijonen, V.
    Rautiainen, M.
    Keskimaki, S.
    Kiviluoto, K.
    Ahtiainen, V.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S844 - S844
  • [44] Dose Escalation Experience with 177Lu-PSMA-617
    Rathke, H.
    Giesel, F. L.
    Flechsig, P.
    Kopka, K.
    Mier, W.
    Hohenfellner, M.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S280 - S281
  • [45] PSMA Radioligand Therapy (PRLT) using Lu-177 PSMA I&T and Lu-177 PSMA-617: Intra-individual comparison of kinetics and dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [46] Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis
    Tauber, R. L.
    Knorr, K.
    Schwaiger, S.
    Retz, M.
    Maurer, T.
    D'Alessandria, C.
    Wester, H-J.
    Gschwend, J.
    Weber, W.
    Schwaiger, M.
    Heck, M. M.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 291 - 291
  • [47] Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
    Tuchayi, Abuzar Moradi
    Yadav, Surekha
    Jiang, Fei
    Kim, Sarasa T.
    Saelee, Rachelle K.
    Morley, Amanda
    Juarez, Roxanna
    Lawhn-Heath, Courtney
    Wang, Yingbing
    de Kouchkovsky, Ivan
    Hope, Thomas A.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (05) : 735 - 739
  • [48] Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    Murthy, Vishnu
    Gafita, Andrei
    Thin, Pan
    Nguyen, Kathleen
    Grogan, Tristan
    Shen, John
    Drakaki, Alexandra
    Rettig, Matthew
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1737 - 1743
  • [49] Radioligand Treatment with [177Lu]Lu-PSMA I&T in the Older Patients - Safety, Efficacy, and Prognostic Factors for Survival
    Weber, Simon
    Seitz, Anna
    Kuebler, Hubert
    Buck, Andreas
    Werner, Rudolf
    Hartrampf, Philipp
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [50] 177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T
    Bundschuh, Ralph A.
    Pfob, Christian H.
    Wienand, Georgine
    Dierks, Alexander
    Kircher, Malte
    Lapa, Constantin
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) : 337 - 338
12345